N-Acetyl Cystein and Contrast Nephropathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 549 participants.
Also called NCT01820195
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 549 participants
- Sponsor
- Imam Khomeini Hospital
- Registry
-
NCT01820195
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Iran
- Registry status
- Unknown status
Technical summary
Registry record NCT01820195. Randomized; double masking; primary purpose prevention. Start 2013-03 (registry gives no type); primary completion 2014-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- N-Acetyl Cystein and Contrast Nephropathy
- Condition
- Chronic Kidney Disease Stage 2
- Condition
- Radiographic Contrast Agent Nephropathy
- Intervention (Drug)
- Oral N-Acetyl Cystein
- Intervention (Drug)
- IV N-Acetyl Cystein
- Intervention (Drug)
- Placebo group
- Lead sponsor
- Imam Khomeini Hospital
- Collaborator
- Tehran Heart Center
Record details
- Record id
cardio:ct-nct01820195- Content hash
6aed5c4d2118c25461a88ebf90e096f74ed8351b4be05857af5710e8e20613cd